RESEARCHER PROFILE
Catrin Lutz
C
Oncode Institute
Catrin Lutz works in Fibroblast Growth Factor Research, Cancer Cells and Metastasis, Breast Cancer Treatment Studies, Cancer Genomics and Diagnostics, TGF-β signaling in diseases. Recorded institutional associations include The Netherlands Cancer Institute, Oncode Institute.
89Publications
810Citations
12H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
2018 · 155 citationsMYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling
2022 · 144 citationsTruncated FGFR2 is a clinically actionable oncogene in multiple cancers
2022 · 121 citationsComparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
2019 · 70 citationsIn situ CRISPR‐Cas9 base editing for the development of genetically engineered mouse models of breast cancer
2020 · 60 citationsHomologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers
2023 · 47 citationsThe Diagnostic Accuracy of Methylation Markers in Urine for The Detection of Bladder Cancer: A Systematic Review
2018 · 37 citationsA living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression
2023 · 34 citationsMechanisms that clear mutations drive field cancerization in mammary tissue
2024 · 31 citationsLuminal breast cancer identity is determined by loss of glucocorticoid receptor activity
2023 · 25 citationsRat Models of Hormone Receptor-Positive Breast Cancer
2024 · 22 citationsPublisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
2022 · 16 citationsFasting boosts breast cancer therapy efficacy via glucocorticoid activation
2025 · 11 citationsEmerging roles of cohesin-STAG2 in cancer
2024 · 10 citationsMYC promotes immune-suppression in TNBC via inhibition of IFN signaling
2021 · 9 citationsLarge-scale Characterization of Orthotopic Cell Line–Derived Xenografts Identifies TGFβ Signaling as a Key Regulator of Breast Cancer Morphology and Aggressiveness
2025 · 6 citationsThe complex landscape of luminal breast cancer
2024 · 5 citationsThe C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
2025 · 2 citationsC-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3
2025 · 2 citationsAbstract IA012: Mammary epithelial architecture modulates field cancerization
2022 · 1 citationsAbstract PR003: Pioneering genetic rat models of Ductal Carcinoma in situ (DCIS)
2022 · 1 citationsAbstract LB_B04: Deciphering FGFR3-TACC3 oncogenic fusions
2023 · 1 citationsAbstract A01: Somatic engineering of the mammary gland for the development of novel mouse models of triple-negative breast cancer
2018 · 0 citationsAbstract 5115: Establishing tumoroid and mouse models for functional validation of progression markers in DCIS
2018 · 0 citationsAbstract B37: Understanding DCIS initiation and progression using PDX and genetically engineered mouse and rat models
2020 · 0 citations
